Gene therapy for Parkinson's disease: Strategies for the local production of dopamine

Gene Therapy and Regulation

Volumn 5, Issue 1, 2010, Pages 57-65

  Muramatsu, Shin Ichi ^a   Asari, Sayaka ^a   Fujimoto, Ken Ichi ^a   Ozawa, Keiya ^a   Nakano, Imaharu ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Adeno associated virus; aromatic L amino acid decarboxylase; guanosine triphosphate cyclohydrolase I; L dopa; positron emission tomography

Indexed keywords

AMINO ACID DECARBOXYLASE; DECARBOXYLASE INHIBITOR; DOPAMINE; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; LEVODOPA; PARVOVIRUS VECTOR; TYROSINE 3 MONOOXYGENASE;

CLINICAL TRIAL; CONFERENCE PAPER; CORPUS STRIATUM; DOPAMINE METABOLISM; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MEGADOSE; DYSKINESIA; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HUMAN; LOW DRUG DOSE; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; TREATMENT RESPONSE;

ADENO-ASSOCIATED VIRUS; EQUINE INFECTIOUS ANEMIA VIRUS;

EID: 78149456640     PISSN: 13889532     EISSN: 15685586     Source Type: Journal    
DOI: 10.1142/S1568558610000173     Document Type: Conference Paper

References (34)

1. Aarsland, D., Marsh, L. and Schrag, A. (2009). Neuropsychiatric symptoms in Parkinson's disease. Mov Disord, 24: 2175-2186.
2. Ahlskog, J. E. and Muenter, M. D. (2001). Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord, 16: 448-458.
3. Bankiewicz, K. S., Eberling, J. L., Kohutnicka, M., Jagust, W., Pivirotto, P., Bringas, J., Cunningham, J., Budinger, T. F. and Harvey-White, J. (2000). Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol, 164: 2-14.
4. Bankiewicz, K. S., Forsayeth, J., Eberling, J. L., Sanchez-Pernaute, R., Pivirotto, P., Bringas, J., Herscovitch, P., Carson, R. E., Eckelman, W., Reutter, B. and Cunningham, J. (2006). Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther, 14: 564-570.
5. Bruck, A., Aalto, S., Rauhala, E., Bergman, J., Marttila, R. and Rinne, J. O. (2009). A follow-up study on 6-[18F]fluoro-l-dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen. Mov Disord, 24: 1009-1015.
6. Christine, C.W., Starr, P. A., Larson, P. S., Eberling, J. L., Jagust, W. J., Hawkins, R. A., VanBrocklin, H. F., Wright, J. F., Bankiewicz, K. S. and Aminoff, M. J. (2009). Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology, 73: 1662-1669.
7. Daya, S. and Berns, K. I. (2008). Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev, 21: 583-593.
8. Dickson, D. W., Braak, H., Duda, J. E., Duyckaerts, C., Gasser, T., Halliday, G. M., Hardy, J., Leverenz, J. B., Del Tredici, K., Wszolek, Z. K. and Litvan, I. (2009). Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol, 8: 1150-1157.
9. Driver, J. A., Logroscino, G., Gaziano, J. M. and Kurth, T. (2009). Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology, 72: 432-438.
10. Evans, A. H., Strafella, A. P., Weintraub, D. and Stacy, M. (2009). Impulsive and compulsive behaviors in Parkinson's disease. Mov Disord, 24: 1561-1570.
11. Fan, D. S., Ogawa, M., Fujimoto, K. I., Ikeguchi, K., Ogasawara, Y., Urabe, M., Nishizawa, M., Nakano, I., Yoshida, M., Nagatsu, I., Ichinose, H., Nagatsu, T., Kurtzman, G. J. and Ozawa, K. (1998). Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic l-amino acid decarboxylase genes using two separate adeno-associated virus vectors. Hum Gene Ther, 9: 2527-2535.
12. Fearnley, J. M. and Lees, A. J. (1991). Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain, 114 (Pt 5): 2283-2301.
13. Forsayeth, J. R., Eberling, J. L., Sanftner, L. M., Zhen, Z., Pivirotto, P., Bringas, J., Cunningham, J. and Bankiewicz, K. S. (2006). A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys. Mol Ther, 14: 571-577.
14. Fox, S. H. and Lang, A. E. (2008). Levodopa-related motor complications-phenomenology. Mov Disord, 23 Suppl 3: S509-S514.
15. Hoshiga, M., Hatakeyama, K., Watanabe, M., Shimada, M. and Kagamiyama, H. (1993). Autoradiographic distribution of [14C]tetrahydrobiopterin and its developmental change in mice. J Pharmacol Exp Ther, 267: 971-978.
16. Kaplitt, M. G. (2010). Parkinson disease: Another player in gene therapy for Parkinson disease. Nat Rev Neurol, 6: 7-8.
17. Kaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., Bland, R. J., Young, D., Strybing, K., Eidelberg, D. and During, M. J. (2007). Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet, 369: 2097-2105.
18. Li, X. G., Okada, T., Kodera, M., Nara, Y., Takino, N., Muramatsu, C., Ikeguchi, K., Urano, F., Ichinose, H., Metzger, D., Chambon, P., Nakano, I., Ozawa, K., Muramatsu, S. (2006). Viral-mediated temporally controlled dopamine production in a rat model of Parkinson disease. Mol Ther, 13: 160-166.
19. Marks, W. J. Jr., Ostrem, J. L., Verhagen, L., Starr, P. A., Larson, P. S., Bakay, R. A., Taylor, R., Cahn-Weiner, D. A., Stoessl, A. J., Olanow, C. W. and Bartus, R. T. (2008). Safety and tolerability of intraputaminal delivery of CERE-120 (adenoassociated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: An open-label, phase I trial. Lancet Neurol, 7: 400-408.
20. Muramatsu, S., Fujimoto, K., Ikeguchi, K., Shizuma, N., Kawasaki, K., Ono, F., Shen, Y., Wang, L., Mizukami, H., Kume, A., Matsumura, M., Nagatsu, I., Urano, F., Ichinose, H., Nagatsu, T., Terao, K., Nakano, I. and Ozawa, K. (2002). Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum Gene Ther, 13: 345-354.
21. Muramatsu, S., Tsukada, H., Nakano, I. and Ozawa, K. (2005). Gene therapy for Parkinson's disease using recombinant adeno-associated viral vectors. Expert Opin Biol Ther, 5: 663-671.
22. Muramatsu, S. I., Fujimoto, K. I., Kato, S., Mizukami, H., Asari, S., Ikeguchi, K., Kawakami, T., Urabe, M., Kume, A., Sato, T., Watanabe, E., Ozawa, K. and Nakano, I. (2010). A Phase I Study of Aromatic l-Amino Acid Decarboxylase Gene Therapy for Parkinson's Disease. Mol Ther (Epub 2010 July 6).
23. Nagatsu, T. and Sawada, M. (2007). Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. J Neural Transm Suppl, 113-120.
24. Nagatsu, T., Horikoshi, T., Sawada, M., Nagatsu, I., Kondo, T., Iizuka, R., Narabayashi, H. (1987). Biosynthesis of tetrahydrobiopterin in parkinsonian human brain. Adv Neurol, 45: 223-226.
25. Nandhagopal, R., Kuramoto, L., Schulzer, M., Mak, E., Cragg, J., Lee, C. S., McKenzie, J., McCormick, S., Samii, A., Troiano, A., Ruth, T. J., Sossi, V., de la Fuente-Fernandez, R., Calne, D. B. and Stoessl, A. J. (2009). Longitudinal progression of sporadic Parkinson's disease: A multi-tracer positron emission tomography study. Brain, 132: 2970-2979.
26. Nutt, J. G. (2008). Pharmacokinetics and pharmacodynamics of levodopa. Mov Disord 23 Suppl 3: S580-S584.
27. Nuytemans, K., Theuns, J., Cruts, M. and Van Broeckhoven, C. (2010). Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: A mutation update. Hum Mutat, 31: 763-780.
28. Oxford BioMedica (2010). Two-year phase I/II results of ProSavin in Parkinson's disease. http://www.oxfordbiomedica.co.uk.
29. Sanchez-Pernaute, R., Harvey-White, J., Cunningham, J. and Bankiewicz, K. S. (2001). Functional effect of adeno-associated virus mediated gene transfer of aromatic l-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats. Mol Ther, 4: 324-330.
30. Sethi, K. (2008). Levodopa unresponsive symptoms in Parkinson disease. Mov Disord, 23 Suppl 3: S521-S533.
31. Shen, Y., Muramatsu, S., Ikeguchi, K., Fujimoto, K., Fan, D. S., Ogawa, M., Mizukami, H., Urabe, M., Kume, A., Nagatsu, I., Urano, F., Suzuki, T., Ichinose, H., Nagatsu, T., Monahan, J., Nakano, I. and Ozawa, K. (2000). Triple transduction with adenoassociated virus vectors expressing tyrosine hydroxylase, aromatic-l-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease. Hum Gene Ther, 11: 1509-1519.
32. Tsuji, S. (2010). Genetics of neurodegenerative diseases: Insights from high-throughput resequencing. Hum Mol Genet, 19: R65-R70.
33. Voon, V., Fernagut, P. O.,Wickens, J., Baunez, C., Rodriguez, M., Pavon, N., Juncos, J. L., Obeso, J. A. and Bezard, E. (2009). Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol, 8: 1140-1149.
34. Zhong, X. H., Haycock, J. W., Shannak, K., Robitaille, Y., Fratkin, J., Koeppen, A. H., Hornykiewicz, O. and Kish, S. J. (1995). Striatal dihydroxyphenylalanine decarboxylase and tyrosine hydroxylase protein in idiopathic Parkinson's disease and dominantly inherited olivopontocerebellar atrophy. Mov Disord, 10: 10-17.